Table 2 Crude and age-sex standardised mortality rates for all-cause and cause-specific mortality
Group | Number of deaths | Person-years | Crude mortality rate/1000 pereson-years (95% CI) | Standardised mortality rate/1000 person-years (95% CI) | Excess risk/1000 person-years (95% CI) |
|---|---|---|---|---|---|
All-cause mortality | |||||
 All | 599 | 37,209 | 16.1 (14.9–17.4) | 16.1 (14.8–17.4) |  |
 Mirtazapine | 213 | 6361 | 33.5 (29.3–38.3) | 21.6 (18.5–25.0) | Reference |
 SSRI | 251 | 23,224 | 10.8 (9.6–12.2) | 13.8 (12.1–15.6) | − 7.8 (− 9.7 to − 5.9) |
 Amitriptyline | 107 | 4744 | 22.6 (18.7–27.3) | 17.6 (14.3–21.5) | − 4.0 (− 6.0 to − 2.0) |
 Venlafaxine | 28 | 2880 | 9.7 (6.7–14.1) | 18.9 (11.3–29.2) | − 2.6 (− 4.7 to − 0.6) |
Deaths due to diseases of the circulatory system | |||||
 All | 159 | 37,209 | 4.3 (3.7–5.0) | 4.3 (3.6–5.0) |  |
 Mirtazapine | 51 | 6361 | 8.0 (6.1–10.5) | 4.8 (3.5–6.5) | Reference |
 SSRI | 73 | 23,224 | 3.1 (2.5–4.0) | 4.0 (3.2–5.1) | − 0.7 (− 1.7 to 0.2) |
 Amitriptyline | 28 | 4744 | 5.9 (4.1–8.5) | 4.3 (2.8–6.4) | − 0.5 (− 1.4 to 0.5) |
 Venlafaxine | 7 | 2880 | 2.4 (1.2–5.1) | 7.0 (2.4–14.9) | 2.2 (1.1 to 3.3) |
Deaths due to diseases of the respiratory system | |||||
 All | 106 | 37,209 | 2.8 (2.4–3.4) | 2.8 (2.3–3.4) |  |
 Mirtazapine | 37 | 6361 | 5.8 (4.2–8.0) | 3.6 (2.5–5.1) | Reference |
 SSRI | 45 | 23,224 | 1.9 (1.4–2.6) | 2.6 (1.9–3.4) | − 1.0 (− 1.8 to − 0.3) |
 Amitriptyline | 17 | 4744 | 3.6 (2.2–5.8) | 2.6 (1.5–4.4) | − 1.0 (− 1.8 to − 0.2) |
 Venlafaxine | 7 | 2880 | 2.4 (1.2–5.1) | 4.0 (1.2–9.5) | 0.4 (− 0.5 to 1.3) |
Deaths due to neoplasms | |||||
 All | 156 | 37,209 | 4.2 (3.6–4.9) | 4.2 (3.6–4.9) |  |
 Mirtazapine | 55 | 6361 | 8.6 (6.6–11.3) | 6.0 (4.4–8.0) | Reference |
 SSRI | 55 | 23,224 | 2.4 (1.8–3.1) | 3.0 (2.2–3.9) | − 3.0 (− 3.9 to − 2.0) |
 Amitriptyline | 38 | 4744 | 8.0 (5.8–11.0) | 6.4 (4.4–8.9) | 0.4 (− 0.7 to 1.6) |
 Venlafaxine | 8 | 2880 | 2.8 (1.4–5.6) | 3.4 (1.4–7.3) | − 2.6 (− 3.5 to − 1.6) |